Global Non-small Cell Lung Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • receipt Report ID : 153689
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 119
  • list Pharmaceuticals and Healthcare

Lung cancer is one of the most common malignant tumors in the world and has become the number one cause of death in malignant tumors in urban population in China. Non-small cell lung cancer accounts for about 80% of all lung cancers, and about 75% of patients are already in the advanced stage, and the 5-year survival rate is very low.

Scope of the Report:

This report studies the Non-small Cell Lung Cancer Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-small Cell Lung Cancer Therapeutics market by product type and applications/end industries.

The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth.This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

The global Non-small Cell Lung Cancer Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-small Cell Lung Cancer Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Bristol-Myers Squibb Company

Orion Corporation

Merck KGaA

AstraZeneca

F. Hoffmann-La Roche Ltd

Pfizer, Inc.

GlaxoSmithKline (GSK) Plc.

Novartis AG

Eli Lilly and Company

Sanofi

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Alimta

Iressa

Avastin

Tarceva

Zykadia

Tagrisso

Others

Market Segment by Applications, can be divided into

Hospitals

Research Institutes

Diagnostic Centers

Others

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Non-small Cell Lung Cancer Therapeutics Market Overview

1.1 Product Overview and Scope of Non-small Cell Lung Cancer Therapeutics

1.2 Classification of Non-small Cell Lung Cancer Therapeutics by Types

1.2.1 Global Non-small Cell Lung Cancer Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Types in 2017

1.2.3 Alimta

1.2.4 Iressa

1.2.5 Avastin

1.2.6 Tarceva

1.2.7 Zykadia

1.2.8 Tagrisso

1.2.9 Others

1.3 Global Non-small Cell Lung Cancer Therapeutics Market by Application

1.3.1 Global Non-small Cell Lung Cancer Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Research Institutes

1.3.4 Diagnostic Centers

1.3.5 Others

1.4 Global Non-small Cell Lung Cancer Therapeutics Market by Regions

1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Non-small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Non-small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Non-small Cell Lung Cancer Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 Bristol-Myers Squibb Company

2.1.1 Business Overview

2.1.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Orion Corporation

2.2.1 Business Overview

2.2.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Orion Corporation Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Merck KGaA

2.3.1 Business Overview

2.3.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Merck KGaA Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 AstraZeneca

2.4.1 Business Overview

2.4.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 F. Hoffmann-La Roche Ltd

2.5.1 Business Overview

2.5.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pfizer, Inc.

2.6.1 Business Overview

2.6.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pfizer, Inc. Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.7 GlaxoSmithKline (GSK) Plc.

2.7.1 Business Overview

2.7.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 GlaxoSmithKline (GSK) Plc. Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.8 Novartis AG

2.8.1 Business Overview

2.8.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Novartis AG Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.9 Eli Lilly and Company

2.9.1 Business Overview

2.9.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Eli Lilly and Company Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.10 Sanofi

2.10.1 Business Overview

2.10.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Sanofi Non-small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Non-small Cell Lung Cancer Therapeutics Market Competition, by Players

3.1 Global Non-small Cell Lung Cancer Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Non-small Cell Lung Cancer Therapeutics Players Market Share

3.2.2 Top 10 Non-small Cell Lung Cancer Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Non-small Cell Lung Cancer Therapeutics Market Size by Regions

4.1 Global Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Regions

4.2 North America Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Non-small Cell Lung Cancer Therapeutics Revenue by Countries

5.1 North America Non-small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)

5.2 USA Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Non-small Cell Lung Cancer Therapeutics Revenue by Countries

6.1 Europe Non-small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue by Countries

7.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)

7.2 China Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Non-small Cell Lung Cancer Therapeutics Revenue by Countries

8.1 South America Non-small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Non-small Cell Lung Cancer Therapeutics by Countries

9.1 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Non-small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Non-small Cell Lung Cancer Therapeutics Market Segment by Type

10.1 Global Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Non-small Cell Lung Cancer Therapeutics Market Forecast by Type (2018-2023)

10.3 Alimta Revenue Growth Rate (2013-2023)

10.4 Iressa Revenue Growth Rate (2013-2023)

10.5 Avastin Revenue Growth Rate (2013-2023)

10.6 Tarceva Revenue Growth Rate (2013-2023)

10.7 Zykadia Revenue Growth Rate (2013-2023)

10.8 Tagrisso Revenue Growth Rate (2013-2023)

10.9 Others Revenue Growth Rate (2013-2023)

11 Global Non-small Cell Lung Cancer Therapeutics Market Segment by Application

11.1 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Non-small Cell Lung Cancer Therapeutics Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Research Institutes Revenue Growth (2013-2018)

11.5 Diagnostic Centers Revenue Growth (2013-2018)

11.6 Others Revenue Growth (2013-2018)

12 Global Non-small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)

12.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)

12.2 Global Non-small Cell Lung Cancer Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Non-small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Non-small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Non-small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Non-small Cell Lung Cancer Therapeutics Picture

Table Product Specifications of Non-small Cell Lung Cancer Therapeutics

Table Global Non-small Cell Lung Cancer Thera

Please fill the form below, to recieve the report sample


+1